In8bio, Inc. (INAB) — SEC Filings
In8bio, Inc. (INAB) — 36 SEC filings. Latest: 8-K (Dec 19, 2025). Includes 22 8-K, 6 10-Q, 2 DEF 14A.
View In8bio, Inc. on SEC EDGAR
Overview
In8bio, Inc. (INAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 19, 2025: On December 18, 2025, IN8bio, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on December 19, 2025.
Sentiment Summary
Across 36 filings, the sentiment breakdown is: 3 bearish, 33 neutral. The dominant filing sentiment for In8bio, Inc. is neutral.
Filing Type Overview
In8bio, Inc. (INAB) has filed 22 8-K, 6 10-Q, 1 10-K/A, 2 DEF 14A, 1 SC 13D/A, 1 SC 13G, 2 SC 13G/A, 1 10-K with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (36)
Risk Profile
Risk Assessment: Of INAB's 31 recent filings, 3 were flagged as high-risk, 17 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$14.498M |
| EPS | -$4.10 |
| Debt-to-Equity | 0.27 |
| Cash Position | $10.689M |
| Operating Margin | N/A |
| Total Assets | $16.768M |
| Total Debt | $3.579M |
Key Executives
- Dr. Lawrence M. Cohen
- AARON GLENN
- LOUIS FLETCHER
- LESLIE WAYNE KREIS, JR.
- Ms. Jennifer L. D. Allison
Industry Context
IN8BIO operates in the biotechnology sector, focusing on developing cell-based cancer immunotherapies. This industry is characterized by high R&D costs, long development cycles, significant regulatory hurdles, and intense competition from both established pharmaceutical companies and emerging biotech firms. Success is heavily dependent on clinical trial outcomes and securing substantial funding.
Top Tags
financials (7) · 8-K (5) · biotech (5) · Biotechnology (4) · corporate-filing (4) · 10-Q (4) · sec-filing (3) · IN8BIO (3) · equity-sale (2) · Net Loss (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash | $10.689M | as of September 30, 2025, insufficient for 12 months of operations |
| Net Loss | $14.498M | for the nine months ended September 30, 2025, an improvement from $24.277M in 2024 |
| Accumulated Deficit | $136.154M | as of September 30, 2025, indicating significant historical losses |
| Common Stock Shares Outstanding | 4,634,396 | as of November 3, 2025, after a one-for-thirty reverse stock split |
| Reverse Stock Split Ratio | 1-for-30 | effected in June 2025 to maintain Nasdaq compliance |
| Research and Development Expenses | $7.563M | for the nine months ended September 30, 2025, a decrease from $13.368M in 2024 |
| General and Administrative Expenses | $7.265M | for the nine months ended September 30, 2025, a decrease from $10.007M in 2024 |
| Potential Proceeds from Series B Warrants | $4.1M | if exercised, offering a source of future capital |
| Potential Proceeds from Series C Warrants | $8.1M | if exercised, offering a source of future capital |
| Research and Development Expense | $9.8M | for the three months ended June 30, 2025, down from $11.5M in Q2 2024 |
| General and Administrative Expense | $2.7M | for the three months ended June 30, 2025, down from $2.8M in Q2 2024 |
| Fiscal Year End | 2024 | The period covered by the annual report. |
| Filing Date | May 7, 2025 | The date the amendment was submitted to the SEC. |
| Reporting Period End Date | 2025-03-31 | Indicates the end of the financial quarter being reported. |
| Public Document Count | 14 | Indicates the number of documents included in the filing. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for In8bio, Inc. (INAB)?
In8bio, Inc. has 36 recent SEC filings from Feb 2024 to Dec 2025, including 22 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INAB filings?
Across 36 filings, the sentiment breakdown is: 3 bearish, 33 neutral. The dominant sentiment is neutral.
Where can I find In8bio, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all In8bio, Inc. (INAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for In8bio, Inc.?
Key financial highlights from In8bio, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INAB?
The investment thesis for INAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at In8bio, Inc.?
Key executives identified across In8bio, Inc.'s filings include Dr. Lawrence M. Cohen, AARON GLENN, LOUIS FLETCHER, LESLIE WAYNE KREIS, JR., Ms. Jennifer L. D. Allison.
What are the main risk factors for In8bio, Inc. stock?
Of INAB's 31 assessed filings, 3 were flagged high-risk, 17 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from In8bio, Inc.?
Forward guidance and predictions for In8bio, Inc. are extracted from SEC filings as they are enriched.